Vitamin D Supplementation and COVID-19
Downloads
Coronavirus Disease 2019 (COVID-19) happened due to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. It is the third coronavirus causing a pandemic. Cases of COVID-19 have increased rapidly. Epidemiological studies show droplets as a medium of transmission of this virus. The high rate of transmission and the death rate create urgency on the management of COVID-19. Unfortunately, until now there is no definitive therapy for the SARS-CoV-2 virus. Several potential therapies, including antivirals, immunomodulatory agents, convalescent plasma transfusions, and supportive therapies such as vitamin D supplementation, have been applied in the management of COVID-19. As a hormone, vitamin D has an immunomodulatory effect used in supportive therapy for various immune-related diseases and respiratory system infections. The immunomodulatory effects of vitamin D are strengthening the physical barrier (cell junction), the specific immune system (adaptive immunity), and the non-specific immune system (innate immunity). Vitamin D is known to suppress pro-inflammatory cytokines and increase the production of anti-inflammatory cytokines. In addition, vitamin D also performs as a substantial part in the induction of ACE2 receptors which gives a weighty influence on pathogenesis of COVID-19. Vitamin D deficiency can amplify the risk of infections including COVID-19. Presently, clinical trials of vitamin D supplementation and COVID-19 are limited. This literature review further examined the role of vitamin D supplementation in COVID-19.
Mokhtari T, Hassani F, Ghaffari N, et al. COVID-19 and Multiorgan Failure: A Narrative Review on Potential Mechanisms. J Mol Histol 2020; 51: 613–628.
da Costa VG, Moreli ML, Saivish MV. The Emergence of SARS, MERS and Novel SARS-2 Coronaviruses in the 21st Century. Arch Virol 2020; 165: 1517–1526.
Bassetti M, Vena A, Giacobbe DR. The Novel Chinese Coronavirus (2019-nCoV) Infections: Challenges for Fighting the Storm. European Journal of Clinical Investigation 2020; 50: e13209.
Heydarifard Z, Yavarian J, Malekshahi SS, et al. SARS-CoV-2: An Imperative Maternal-Fetal Concern. Iran J Microbiol 2021; 13: 427–433.
Ardiaria M. Peran Vitamin D dalam Pencegahan Influenza dan COVID-19. JNH (Journal Nutr Heal 2020; 8: 79–85.
Taha R, Abureesh S, Alghamdi S, et al. The Relationship between Vitamin D and Infections Including COVID-19: Any Hopes? Int J Gen Med 2021; 14: 3849–3870.
Murdaca G, Pioggia G, Negrini S. Vitamin D and COVID-19: An Update on Evidence and Potential Therapeutic Implications. Clin Mol Allergy 2020; 18: 23.
Hewison M. Vitamin D and Immune Function: An Overview. Proc Nutr Soc 2012; 71: 50–61.
Maruotti N, Cantatore FP. Vitamin D and the Immune System. J Rheumatol 2010; 37: 491 LP – 495.
Behl T, Shah S, Kaur I, et al. Role of ACE 2 and Vitamin D: The Two Players in Global Fight against COVID-19 Pandemic. Ann Natl Acad Med Sci 2021; 57: 186–196.
Susanto JP. Konsep Baru Renin Angiotensin System (RAS). CDK (Cermin Dunia Kedokteran) 2015; 42: 102–105.
Hussain M, Jabeen N, Amanullah A, et al. Molecular Docking between Human TMPRSS2 and SARS-CoV-2 Spike Protein: Conformation and Intermolecular Interactions. AIMS Microbiol 2020; 6: 350–360.
Al Mheid I, Quyyumi AA. Vitamin D and Cardiovascular Disease: Controversy Unresolved. J Am Coll Cardiol 2017; 70: 89–100.
Yuan W, Pan W, Kong J, et al. 1,25-Dihydroxyvitamin D3 Suppresses Renin Gene Transcription by Blocking the Activity of the Cyclic AMP Response Element in the Renin Gene Promoter*. J Biol Chem 2007; 282: 29821–29830.
Cohen-Lahav M, Shany S, Tobvin D, et al. Vitamin D Decreases NFkappaB Activity by Increasing IkappaBalpha Levels. Nephrol Dial Transplant 2006; 21: 889–897.
van Eijk LE, Binkhorst M, Bourgonje AR, et al. COVID-19: Immunopathology, Pathophysiological Mechanisms, and Treatment Options. J Pathol 2021; 254: 307–331.
Kumagai Y, Takeuchi O, Kato H, et al. Alveolar Macrophages are the Primary Interferon-Alpha Producer in Pulmonary Infection with RNA Viruses. Immunity 2007; 27: 240–252.
Konno Y, Kimura I, Uriu K, et al. SARS-CoV-2 ORF3b is a Potent Interferon Antagonist whose Activity is Increased by a Naturally Occurring Elongation Variant. Cell Rep 2020; 32: 108185.
Channappanavar R, Fehr AR, Vijay R, et al. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe 2016; 19: 181–193.
Li X, Geng M, Peng Y, et al. Molecular Immune Pathogenesis and Diagnosis of COVID-19. J Pharm Anal 2020; 10: 102–108.
Newton AH, Cardani A, Braciale TJ. The Host Immune Response in Respiratory Virus Infection: Balancing Virus Clearance and Immunopathology. Semin Immunopathol 2016; 38: 471–482.
Zhou Y, Fu B, Zheng X, et al. Pathogenic T-Cells and Inflammatory Monocytes Incite Inflammatory Storms in Severe COVID-19 Patients. Natl Sci Rev 2020; 7: 998–1002.
Wu D, Yang XO. TH17 Responses in Cytokine Storm of COVID-19: An Emerging Target of JAK2 Inhibitor Fedratinib. J Microbiol Immunol Infect 2020; 53: 368–370.
Qin C, Zhou L, Hu Z, et al. Dysregulation of Immune Response in Patients with Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 2020; 71: 762–768.
Merzon E, Tworowski D, Gorohovski A, et al. Low Plasma 25(OH) Vitamin D Level is Associated with Increased Risk of COVID-19 Iinfection: An Israeli Population-Based Study. FEBS J 2020; 287: 3693–3702.
Rastogi A, Bhansali A, Khare N, et al. Short Term, High-Dose vitamin D Supplementation for COVID-19 Disease: A Randomised, Placebo-Controlled, Study (SHADE Study). Postgrad Med J 2020; postgradmedj-2020-139065.
Entrenas Castillo M, Entrenas Costa LM, Vaquero Barrios JM, et al. Effect of Calcifediol Treatment and Best Available Therapy Versus Best Available Therapy on Intensive Care Unit Admission and Mortality among Patients Hospitalized for COVID-19: A Pilot Randomized Clinical Study. J Steroid Biochem Mol Biol 2020; 203: 105751.
Murai IH, Fernandes AL, Sales LP, et al. Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients with Moderate to Severe COVID-19: A Randomized Clinical Trial. JAMA 2021; 325: 1053–1060.
Ali N. Role of Vitamin D in Preventing of COVID-19 Infection, Progression and Severity. J Infect Public Health. Epub ahead of print 2020. DOI: https://doi.org/10.1016/j.jiph.2020.06.021.
Raisi-Estabragh Z, McCracken C, Bethell MS, et al. Greater Risk of Severe COVID-19 in Black, Asian and Minority Ethnic Populations is Not Explained by Cardiometabolic, Socioeconomic or Behavioural Factors, or by 25(OH)-Vitamin D Status: Study of 1326 Cases from the UK Biobank. J Public Health (Oxf) 2020; 42: 451–460.
Copyright (c) 2022 Gracia Dewitacita Tanaya, Willa Mettacita Tanaya, Ayu Hutami Syarif
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.
JR (